Eyenovia, Inc.’s Post

Akums Drugs and Pharmaceuticals, a prominent CDMO player, made a subdued debut on the stock market, listing at Rs. 750 per share, reflecting a modest 10% gain over its issue price of Rs. 679. While the IPO received a strong subscription of 63.44 times and the initial market buzz was positive, the actual listing fell short of expectations, likely influenced by the prevailing market volatility.The company's strong fundamentals and market position offer potential for long-term growth, but investors should carefully assess the risks and market volatility. Investors with a long-term view may hold their position by keeping a stop loss at its issue price.

Investors, important. As I was right about Swvl Holdings Corp. (SWVL) whose shares rose over 2300% in just a few months, that's what I claimed and it was true. So now I want to draw your attention to another company that is at the beginning of a part of history with its inventions in the field of biopharmaceuticals. It is Tonix Pharmaceuticals Holding Corp. (TNXP). I'm sure these shares will rise above 5000% very soon. And that this growth will continue in the future. https://lnkd.in/efnK_u_G https://lnkd.in/eQ-XtthA https://lnkd.in/e3J9c39e #TonixPharmaceuticalsHoldingCorp. #TNXP

$TFFP - Is Tff Pharmaceuticals Undervalued? Upcoming quarterly report is projected on 13th of February 2024.: About 19.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.08. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Tff Pharmaceuticals recorded a loss per share of 12.75. The entity had not issued any dividends in recent years. The firm had 1:25 split on the 19th of December 2023. #stocks #stocktwits #thematic_portfolio

Technically, $ATNM price is consolidating effectively around $8.00, demonstrating strength as indicated by positive signals from the MACD and RSI. Recent developments may serve as a catalyst to propel the price upward. Keep an eye on movements above $8.15. #premarket #stockmarket #investing #trading Actinium Pharmaceuticals, Inc.

Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF)'s shares rose 5% in early trade on Thursday, buoyed by robust annual results that prompted the company to increase its dividend by nearly a third. The pharmaceutical group reported a 14% rise in full-year revenues to $2.88 billion, with significant growth across its Injectables, Core operating profits climbed 19% to $707 million, reflecting higher margins and improved profitability, particularly in the Branded and Generics segments. The final dividend was raised to 47 cents, up from 37 cents, resulting in a total 2023 dividend of 72 cents—a 29% increase from 2022. Despite this success, Hikma anticipates a slowdown in revenue growth to 4-6% for 2024, with core operating profits expected to range between $660 million and $700 million. More at #Proactive #ProactiveInvestors http://ow.ly/p86Z105jnii

Akums Drugs IPO Allotment and GMP Insights: What to Expect on Listing Day The Akums Drugs and Pharmaceuticals Limited IPO, which opened on July 30, 2024, and closed on August 1, 2024, has garnered significant attention in the market. Following the completion of the bidding process, the allotment status for the IPO has been released. Investors who applied for this book build issue can now check their application status online through the BSE website or Link Intime's official website. IPO Allotment Status Check For those eager to check their allotment status, the process is straightforward. You can log in to the BSE website or visit Link Intime's portal. Link Intime Private Limited serves as the official registrar for this IPO, ensuring a smooth allotment process for all investors. Grey Market Premium (GMP) Insights As of today, the Grey Market Premium (GMP) for Akums Drugs stands at ₹110, a notable decrease from ₹140 on Friday. Market analysts attribute this decline to last week's global market turbulence, which saw significant selling across Asian, European, and US stock markets. Despite this dip, the GMP suggests a potential listing gain of around 16% for those who have been allotted shares. Listing Date and Expectations With the 'T+3' listing rule in effect, Akums Drugs is expected to debut on the stock market on Tuesday, August 6, 2024. The current GMP indicates that the anticipated listing price could be around ₹789 (₹679 + ₹110), representing a premium over the IPO's upper price band. Final Thoughts While the GMP offers a glimpse into market sentiment, it's crucial to approach investment decisions with caution. The above information reflects market observers' views and should not be considered as financial advice. Investors are encouraged to consult certified financial experts to make informed decisions. Equivaluesearch #AkumsDrugs #IPO #MarketUpdate #GreyMarketPremium #ListingDay #Investing #Finance #Pharmaceuticals #StockMarket

Emcure Pharma closes 3% higher after making strong market debut; Emcure Pharmaceuticals, backed by Namita Thapar, made a remarkable debut on the Indian stock exchanges on Wednesday, July 10. The shares were listed at ₹1,325.05 apiece on the BSE, reflecting a 31.45 percent premium over the issue price of ₹1,008. Following the listing, Emcure Pharma's shares climbed further to ₹1,384, marking a 4.5 percent increase from the listing price and a 37.3 percent rise from the IPO price. The stock finally settled at ₹1,361.00, up 2.71 percent from the listing price. Emcure Pharmaceuticals, a leading player in the Indian pharma market, witnessed a strong debut on the stock exchanges, listing at Rs. 1325 per share. This translates to a significant 31.45% gain over its issue price of Rs. 1008. The listing aligns with pre-listing expectations, fueled by the robust investor response.

💊 Are you a fan of investing in Pharmaceutical companies? You'll want to see this... https://lnkd.in/egBz2zGz #NVO #NovoNordisk #StockMarketInsights #stocks #TradingTips #TradingSignals #QQQ #SQQQ #IWM #healthcarestocks

Shares of Wockhardt hit the 5% upper circuit. On March 27, shares of Wockhardt surged, hitting the 5% upper circuit at Rs 557.85 each on the NSE. This increase followed investments from funds associated with prominent investors Madhusudan Kela and Prashant Jain in the company's Rs 480-crore QIP. The pharmaceutical company closed its QIP on March 26 after endorsing the issuance of 92.85 lakh equity shares at a price of Rs 517 per share. Following the QIP, the pharmaceutical company's paid-up equity share capital is set to rise to Rs 76.7 crore, comprising 15.34 crore equity shares. #stockmarket #Investmentstrategy #financialplanning #investmentgoals #financialfreedom #diversifyyourportfolio #InvestmentTips

#News: Aspen Pharmacare Canada (APNJ.J),  fell short of its targeted mid-single digit growth in core profit on Tuesday, but is betting on #GLP1 drug contracts to boost future earnings. Aspen's shares shed 13.23% to 213.60 rand by market close. For the year to June 30, Africa's biggest drugmaker recorded normalised headline earnings per share of 14.92 rand, little changed from the 14.98 rand a year earlier. At its half-year results, Aspen had guided mid-single digit growth in normalised earnings before interest, tax, depreciation and amortisation (EBITDA) for its 2024 financial year. Read more from Reuters 👇🏼